The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma by Tsuda, H et al.
Recent genetic and biochemical investigations of the molecular
mechanisms governing the G1 to S progression in mammalian
cells have demonstrated a central role for D-type cyclins and their
partner kinases cyclin dependent kinase (CDK4) and CDK6
(Kamb et al, 1995; Sherr et al, 1995; Strauss et al, 1995; Weinberg
et al, 1995; Hall et al, 1996). When activated by cyclin D, CDK is
able to phosphorylate retinoblastoma protein (pRb) leading to the
release of associated proteins like E2F that have the capability to
activate genes necessary for cell progression through the G1 phase
(Weinberg et al, 1995). p16 controls cell cycle proliferation during
G1 by inhibiting the ability of cyclin D/CDK4 and cyclin D/CDK6
complexes to phosphorylate pRb (Serrano et al, 1993). The
components of the p16-cyclin D/CDK-pRb pathway are frequently
found to be altered in various types of cancer (Cirns et al, 1995;
Nakagawa et al, 1995; Kinoshita et al, 1996; Barbieri et al, 1997;
Zhang et al, 1997).
In solid tumours, there is a reciprocal correlation between
genetic alterations of single members of the p16-cyclin D/CDK-
pRb pathway (He et al, 1994; Schauer et al, 1994; Bartkova et al,
1996). It has been reported that hypophosphorylated active pRb
can repress p16 expression, whereas inactivation of pRb by phos-
phorylation leads to p16 expression (Li et al, 1994). Consistent
with these findings, CDKN2 gene deletion and Rb deficiency are
reported to be inversely correlated in many types of tumours
(Bartkova et al, 1996; Kinoshita et al, 1996). In addition, a strong
association between altered cyclin D1 and pRb expression has
been reported in oesophageal tumours (Jiang et al, 1993). Muller
et al have demonstrated that the cell cycle-dependent expression of
cyclin D1 in tumour cell lines requires the presence of a functional
pRb (Muller et al, 1994). The expression levels and activities of
these proteins can modulate each other. It is thought to be impor-
tant to evaluate these four elements simultaneously.
Endometrial carcinoma is the most common malignant
neoplasm of the female genital tract; however, its molecular patho-
genetic events are not fully understood. There are few reports
about the abnormalities of p16-cyclin D/CDK-pRb pathway in
endometrial cancer (Peiffer et al, 1995; Niemann et al, 1997;
Shiozawa et al, 1997). Additionally, to our knowledge, there are
no reports in which p16, cyclin D, CDK and pRb were examined
simultaneously in endometrial cancer. In this study, we have
examined all these key components of this G1 checkpoint mecha-
nism by a combination of genetic and immunohistochemical
approaches in normal endometrium (PE), endometrial hyperplasia
(EH) and endometrial cancer (EC).
MATERIALS AND METHODS
Clinical samples
Paraffin-embedded tissue of 35 endometrioid-type endometrial
cancers: (EC) (stage 1: 23; stage 2: five; stage 3: six; stage 4: none;
recurrence: one) and 18 endometrial hyperplasia: (EH) (simple
hyperplasia: 12, atypical hyperplasia: six) were collected at Osaka
City General Hospital, Osaka, Japan. For control specimens,
normal endometrial tissue (proliferative phase endometrium, PE)
was selected from ten patients who had benign uterine leiomyoma.
Histological diagnosis was confirmed by microscopic examination
of the haematoxylin and eosin (H&E)-stained sections according
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mined according to the International Federation of Gynecology
and Obstetrics (FIGO) system. Regions of more than 80% tumour
density were marked on H&E-stained slides to be used as guide-
lines for microdissection. Two 5-mm sections were cut from the
paraffin block and the neoplastic tissue was microdissected away
from contaminating normal tissue. The DNA was extracted using a
DEXPAT™ kit (TaKaRa, Japan) and was finally precipitated in
cold ethanol with sodium acetate and resuspended in Tris–EDTA
buffer, pH 7.5.
PCR-SSCP analysis
Polymerase chain reaction (PCR) was performed using 100 ng of
genomic DNA as template in a 50 ml reaction volume containing 
10 pmol of each rhodamine-labelled oligonucleotide primer, 5 ml of
10 ´ Taq DNA polymerase buffer (Perkin-Elmer, Cetus, CT, USA),
200 mM each dNTP (Perkin-Elmer, Cetus), 5% (v/v) dimethyl
sulphoxide (DMSO) and 1.25 units Taq Gold DNA polymerase
(Perkin-Elmer, Cetus). The primers used to amplify the regions of the
CDKN2 genes are the following (Hussussian et al, 1994): for exon 1,
5¢-GGGAGCAGCATGGAGCCG-3¢ (X1.31F)/5¢-CTGGATCGG-
CCTCCGACCGT-3¢ (MK50) and 5¢-AGCAGCATGGATCC GG-
CGGCGG-3¢ (MK49)/5¢-AGTCGCCCGCCATCCCCT-3¢
(X1.26R); for exon 2, 5¢-AGCTTCCTTCCGTCATGC-3¢ (X2.62F)/
5¢-GCAGCACCACAGCGTG3¢ (286R), 5¢-AGCCCAACT-GCGC-
CGAC-3¢ (200F)/5¢-CCAGGTCCACGGGCAGA-3¢ (346R) and 
5¢-TGGACGTGCGCGATGC-3¢ (305F)/5¢-GGAAGCTCTCAGG-
GGTACAAATTC-3¢ (X2.42R). After a 10 min initial denaturation
step at 94°C, 40 cycles of 30 s at 94°C, 30 s at an annealing tempera-
ture (55–60°C), and 1 min at 72°C were performed in a thermal
cycler (Perkin-Elmer, Cetus).
For single-strand conformational polymorphism (SSCP)
analysis, 1 ml of each PCR product was mixed with 9 ml of SSCP
loading buffer [98% (v/v) formamide, 10 mM EDTA] and incu-
bated at 80°C for 5 min, followed by rapid cooling on ice. Two
microlitres of the sample solution were loaded on a 6% acrylamide
gel containing 1 ´ TBE (86 mM Tris–borate, 2 mM EDTA) and 5%
glycerol. Following electrophoresis at 30 W at room temperature
for 2–3 h, the gel was analysed using an FMBIO 100 fluorescent
image analyser (TaKaRa, Japan). The presence of bands with
variant migration pattern was confirmed by repeating PCR-SSCP
at least once prior to extraction of the band for DNA sequence
analysis.
DNA sequencing
PCR products that revealed mobility shifts on SSCP analysis were
cut from the gels and recovered. Re-amplification by PCR was
followed by subcloning into pAMP1 vector (Gibco-BRL, MD,
USA) and sequencing using M13/pUC primer. The sequence
analysis for each product was performed with an ABI 310 genetic
analyser (Perkin-Elmer, Cetus) and the Dye Terminator Cycle
Sequencing FS Ready Reaction Kit (Perkin-Elmer, Cetus).
Multiplex PCR of CDKN2 gene
The CDKN2 gene homozygous deletion was investigated by PCR
for the ability to amplify a region of the gene compared with the
ability to amplify, as an internal control, the human b-globin gene.
The sequence of the primers used for multiplex PCR were CDKN2
exon 2 (Marchini et al, 1997), sense 5¢-TCTGACCATTCT-
GTTCTCTC and antisense 5¢-AGCACCACCAGCGTGTC;  b-
globin, sense 5¢-CAACTTCATCCACGTTCACC and antisense
5¢-GGTTGGCCAATCTACTCCCAGG. This p16 primer pair
amplifies on the 5¢ half of exon 2, where the majority of p16 muta-
tions in human cancer cells have been described (Maestro et al,
1995). These primers amplify fragments of 166 bp and 205 bp
respectively. One hundred nanograms of genomic DNA was
amplified in a final volume of 50 ml containing 10 pmol of each
oligonucleotide primer, 5 ml of 10 ´ Taq DNA polymerase buffer
(Perkin-Elmer, Cetus), 200 mM each dNTP and 3.75 units Taq
Gold DNA polymerase (Perkin-Elmer, Cetus). The cycles of
amplification were as described previously (Kamb et al, 1994) and
reduced to 30 cycles in the b-globin co-amplification to maintain
the amplification in the exponential phase (Campbell et al, 1995).
Samples were loaded on 4% MetaPhor agarose gel and visualized
by ethidium bromide staining. The signal intensity was analysed
using an FMBIO 100 fluorescent image analyser (TaKaRa, Japan).
The CDKN2 signal intensity was normalized against the b-globin
signal intensity. We considered a tumour to have reduced gene
dosage consistent with possible homozygous deletion of CDKN2
gene in the tumour cells when the normalized CDKN2 signal
intensity in the tumour sample was reduced to less than 80% of
that in the normal uterine control. In order to ascertain
CDKN2/p16 homozygous deletion, each experiment was repeated
two times.
Analysis of methylation in 5¢CpG island in the promoter
region of the p16 gene
The methylation status of the 5¢CpG island in the promoter region
of the p16 gene was determined with the CpGWiz™ p16
Methylation Kit (Oncor, Inc.). Briefly, 0.5–1.0 mg of DNA was
denatured with 3 M sodium hydroxide at 50°C for 10 min and
treated with sodium bisulphite following the manufacturer’s
protocol. After completion of the DNA modification, the DNA
was purified by precipitation. The dissolved DNA was amplified
by PCR, utilizing primers specific for the methylated (M) or
unmethylated (U) sequences. A 5-ml aliquot of template (corre-
sponding to treated DNA, positive control for methylated DNA,
positive control for unmethylated sequences, and distilled water as
negative control) was amplified in the presence of 10 ´ Universal
PCR buffer, 2.5 mM dNTP mix, U or M primers, and AmpliTaq
Gold™ (Perkin-Elmer), under the following conditions: preheating
(95°C, 12 min), followed by 35 cycles (95°C, 45 s; 65°C, 45 s;
72°C, 1 min). The PCR product was analysed on a 2% agarose gel.
The presence of DNA methylation was determined by the identifi-
cation of one 145 bp fragment in those samples amplified with the
M primers. All the cases were evaluated for the presence of an
unmethylated specific fragment (154 bp), which served as an
internal control for the quality of the treated DNA.
Immunohistochemistry of p16, CDK4, CDK6, cyclin D1,
cyclin D2, cyclin D3 and pRb proteins
Histological sections (4 mm) were affixed to glass slides, dewaxed
and rehydrated. Autoclave unmasking process (10 min at 121°C in
10 mM citrate buffer, pH 6.0) was used. The sections were then
incubated in 3% hydrogen peroxide for 10 min at room tempera-
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reacted with one of the following primary antibodies at 4°C
overnight: (a) rabbit anti-p16 polyclonal antibody (Pharmingen,
San Diego, CA, USA), (b) mouse anti-pRb monoclonal antibody
(Pharmingen), (c) rabbit anti-CDK4 polyclonal antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), (d) rabbit anti-
CDK6 polyclonal antibody (Santa Cruz Biotechnology, Inc.), (e)
mouse anti-cyclin D1 monoclonal antibody (Medical and
Biological Laboratories Co., Nagoya, Japan), (f) rabbit anti-cyclin
D2 polyclonal antibody (Santa Cruz Biotechnology, Inc.), (g)
rabbit anti-cyclin D3 polyclonal antibody (Santa Cruz
Biotechnology, Inc.), or nonimmunized rabbit serum. After
rinsing, the sections were incubated for 30 min with mouse or
rabbit EnVision + Peroxidase (Dako, CA, USA). The peroxidase
activity for p16, pRb, CDK4, CDK6, cyclin D1, cyclin D2 and
cyclin D3 was visualized by applying diaminobenzidine chro-
mogen containing 0.05% hydrogen peroxide for 2–10 min at room
temperature. The sections were then counterstained with haema-
toxylin. Positive and negative control experiments were performed
for each tumour staining.
Interpretation of immunohistochemical staining
Evaluation of p16, pRb, CDK4, CDK6, cyclin D1, cyclin D2 and
cyclin D3 positives was performed with semiquantitative analyses.
The following scale was used: 0 = no immunoreactive tumour cells
detectable or less than 5% of the tumour cells were positive with a
weak intensity; 1 = 5–50% of the tumour cells were positive with a
strong intensity; 2 = more than 50% of the tumour cells were posi-
tive with a strong intensity. Tumours were scored as p16-negative
if less than 5% malignant cells had positive nuclear staining, and
surrounding normal stromal cells showed adequate nuclear
staining as a positive internal control. Tumours were regarded as
p16-positive if more than 5% malignant cells had nuclear staining.
Small lymphocytes, which showed no nuclear staining of p16,
were used as a negative internal control (Kratzke et al, 1996).
These criteria were used for evaluation of pRb staining. Negative
nuclei staining (0) was considered as abnormal expression in p16
and pRb. Strong nuclear staining (2) was considered as abnormal
expression of CDK4, CDK6, cyclin D1, cyclin D2 and cyclin D3
(Michalides et al, 1995).
Statistical analysis
The abnormalities of p16, pRb, CDK4, CDK6, cyclin D1, cyclin D2
and cyclin D3 were analysed using Fisher’s exact probability test to
compare the different clinicopathologic groups with each other.
RESULTS
PCR-SSCP analysis of the CDKN2 genes
SSCP analyses were performed for two CDKN2 coding exons.
One SSCP variant pattern was detected in assay for exon 1B in
case 27. DNA sequence analysis of clones of this abnormally
migrating SSCP fragment revealed a point mutation in intron 2.
No mutations of either exons 1 or 2 were found in any samples
(data not shown).
Detection of homozygous deletion of the CDKN2 genes
The comparative multiplex PCR assay was titrated using serial
mixtures of normal human DNA and DNA from a CNS cell line
(SF295) with homozygous deletion of CDKN2/p16 locus.
Reduction of CDKN2/p16 amplification product was indicated
when normal DNA constituted less than 20% of the total DNA
(Figure 1A). In case 48, CDKN2/p16 homozygous deletion was
observed (Figure 1B).
Analysis of methylation in 5¢CpG island in the promoter
region of the p16 gene
Forty-two samples DNA were available for p16 methylation
analysis. Fifteen of 42 samples (35.7%) had methylation in 5¢CpG
island in the promoter region of the p16 gene. Five of 15 EH
(33.3%) and ten of 27 EC (37.0%) had methylation (Figure 2). Of
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Figure 1 (A) The comparative multiplex PCR assay using serial mixtures of
normal human DNA and DNA from a central nervous system cell line
(SF295) with homozygous deletion of CDKN2/p16 locus. M: size marker; N:
negative control; lane 1: SF295 DNA:normal DNA = 10:0; lane 2: 9.5:0.5;
lane 3: 9:1; lane 4: 8:2; lane 5: 7:3; lane 6: 6:4; lane 7: 0:10. Reduction of
CDKN2/p16 amplification product was detected when normal DNA
constituted less than 20% of the total DNA. (B) Multiplex PCR of CDKN2/p16
locus in cases 41, 48 and 52. CDKN2/p16 homozygous deletion was
observed in case 48
Figure 2 Analysis of methylation in 5¢CpG island in the promoter region of
the p16 gene. Primer sets used for amplification are designed as
unmethylated (U) or methylated (M). Lane 1: size marker; lanes 2, 4, 6 and
8: PCR products with U primer in cases 2, 14, 24 and 37, respectively; lanes
3, 5, 7 and 9: PCR products with M primer in cases 2, 14, 24 and 37,
respectively; lane 10: unmethylated DNA with U primer; lane 11: methylated
DNA with M primer678 H Tsuda et al
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Table 1 Endometrial hyperplasia
Case Age Histology SSCP Methylation HD p16 CDK4 CDK6 CCND1 CCND2 CCND3 pRb
1 7 8 S H N M N1000001
2 4 6 S H NUN1100001
3 6 6 S H NUN1100001
4 4 5 S H NUN1100001
5 4 9 S H N N D N1110001
6 4 6 S H NUN1100001
7 4 8 S H N N D N1200001
8 4 7 S H N M N0000001
9 5 2 S H N M N0000001
1 0 5 4 S H NUN0100001
1 1 7 0 S H N N D N0100002
1 2 5 1 S H NUN0100001
1 3 8 2 A H NUN1100001
1 4 8 3 A H N M N0110001
1 5 2 2 A H NUN1100001
1 6 5 2 A H NUN0100001
1 7 5 0 A H N M N0100002
1 8 7 4 A H NUN0000001
AH: atypical hyperplasia; SH: simple hyperplasia; N: normal; ND: not done.
Table 2 Endometrial cancer
Case Age Stage Grade SSCP Methylation HD p16 CDK4 CDK6 CCND1 CCND2 CCND3 pRb
1 9 5 9 1 a 1NUN1000002
2 0 3 9 1 a 1NUN1200001
2 1 5 3 1 a 2N M N1100001
2 2 5 5 1 a 2N N D N1211002
2 3 6 7 1 a 2N M N2100001
2 4 6 7 1 b 1NUN1100001
2 5 5 1 1 b 1N M N1000002
2 6 7 3 1 b 1NUN1100001
2 7 6 0 1 b 1AUN1000000
2 8 5 6 1 b 1NUN1200002
2 9 5 4 1 b 1NUN1100001
3 0 4 4 1 b 1N N D N1200002
3 1 5 9 1 b 2N N D N2000001
3 2 5 8 1 b 2N M N0101001
3 3 5 2 1 b 2NUN1210001
3 4 7 7 1 b 2NUN1101001
3 5 6 5 1 b 2NUN1100001
3 6 5 5 1 b 2NUN1000002
3 7 5 4 1 b 3N M N0100001
3 8 6 2 1 b 3N N D N2200000
3 9 4 2 1 c 1N M N1101001
4 0 5 4 1 c 2NUN1001001
4 1 5 2 1 c 2N M N0001000
4 2 4 5 2 a 1N N D N1201001
4 3 4 8 2 a 1N M N1101001
4 4 5 2 2 a 2N N D N1201001
4 5 6 8 2 b 1N M N1100002
4 6 8 0 2 b 3N N D N1201001
4 7 3 7 3 a 1NUN1200000
4 8 7 2 3 a 1– N D H D 0020101
4 9 6 0 3 a 3NUN1101001
5 0 5 3 3 c 1NUN1100001
5 1 6 0 3 c 1NUN0100001
5 2 5 6 3 c 3NUN0210001
5 3 5 7 R E 2N M N1200001
N: normal; A: abnormal; U: unmethylated; M: methylated; ND: not done; HD: homozygous deletionp16-cyclin D/CDK-pRb pathway in endometrial cancer 679
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Figure 3 Typical images of p16, pRb, CDK4, CDK6, cyclin D1, cyclin
D2 and cyclin D3 staining. (A) Positive p16 immunostaining of case 47.
(B) Negative p16 immunostaining of case 48. The section shows
negative nuclear staining of the tumour cells. (C) Positive pRb
immunostaining of case 48. (D) Negative pRb immunostaining of case
47. Note that stromal cells show distinct nuclear staining (arrow) of p16
and pRb, which provide positive internal controls for both proteins. (E)
Strong positive CDK4 immunostaining in case 53. (F) Strong positive
CDK6 immunostaining in case 48. (G) Strong positive cyclin D1
immunostaining in positive control. (H) Strong positive cyclin D2
immunostaining in positive control. (I) Strong positive cyclin D3
immunostaining in positive control. (A–I, original magnification 200 3)nine p16 (–) EH and six p16 (–) EC, four (44.4%) and three
(50.0%) had methylation respectively. Of five methylated EH, four
(80%) cases had no expression of p16 and of ten methylated EC,
three (30%) cases had no expression of p16.
Immunohistochemistry of p16, pRb, CDK4, CDK6,
cyclin D1, cyclin D2 and cyclin D3 proteins
The results of immunohistochemical analysis are shown in Tables
1 and 2. Two of ten PE (20%), nine of 18 EH (50.0%) and 29 of 35
EC (82.9%) had p16 nuclear staining. In the six p16 (–) EC, one
was considered to have reduced gene dosage consistent with
possible homozygous deletion of the CDKN2 gene and three had
methylation in 5¢CpG island in the promoter region of the p16
gene, wheres none showed such reduced gene dosage and four had
methylation in the nine p16 (–) EH. p16 expression was signifi-
cantly higher in EC than EH (P = 0.0119). pRb was detectable in
all ten of ten PE, all 18 of 18 EH and 31 of 35 EC; pRb was not
detectable in four of 35 EC (11.4%). The EC cases with loss of
either p16 or pRb expression are 1bG2, 1bG3, 1cG2, 3aG1, 3cG1,
3cG3, 1bG1, 1bG3, and 3aG1. Typical images of p16 and pRb
staining are shown in Figure 3 A–D.
In total, two of ten PE (20%), 14 of 18 EH (77.8%) and 27 of 35
EC (77.1%) exhibited positive nuclear staining with CDK4 anti-
body. Strong CDK4 staining was observed in 12 of 35 EC (34.3%)
and one of 18 EH (5.6%). The strong expression of CDK4 was
higher in EC than in EH (P = 0.0399). The weak and strong
expression of CDK4 was higher in EH than PE (P = 0.0054). The
strong expression of CDK4 was higher in cases with grade 3
tumours (60.0%) than with grade 1 tumours (29.4%), but this
difference was not significant. Ten cases of EC exhibited weak
positive nuclear staining of cyclin D1 and its expression was
higher in EC than EH (P = 0.0118). In contrast, the expression of
CDK6, cyclin D2 and cyclin D3 was rare in EC. Representative
pictures of CDK4, CDK6, cyclin D1, cyclin D2 and cyclin D3
staining are shown in Figure 3 E–I. The abnormalities of p16-
cyclin D/CDK-pRb pathway were detected in 18 of 35 EC
(51.4%). Correlation of expression of p16, pRb, CDK4, CDK6,
cyclin D1, cyclin D2 and cyclin D3 and clinicopathologic features
are shown in Table 3.
DISCUSSION
It was reported that the alterations of CDKN2 were uncommon and
late events in endometrial cancers (Peiffer et al, 1995; Milde-
Langosch et al, 1999). In contrast, Shiozawa et al (1997) reported
that in endometrial cancer, 65.8% of examined cases were
negative for p16 protein. In our study, the rate of absence of p16
expression in EC was 17.1%. Based on our study, p16 alterations
are thought to be rare in endometrial cancer. In our studies cases,
the rate of absence of pRb expression in EC was low (11.4%). It
was reported that alterations of pRb were rare events (Niemann et
al, 1997; Milde-Langosch et al, 1999). In particular, Yaginuma et
al (1996) demonstrated that Rb gene abnormality was a rare event
in endometrial cancer. Geradts et al (1996) reported that studies on
the expression of Rb in neoplasms will include an unknown, but
probably small, number of positive stains despite the lack of func-
tional pRb. The pRb alterations are thought to be rare in endo-
metrial cancer. Further examination will be required to solve this
problem.
There were no cases exhibiting overexpression of cyclin D1 in
this study. Cyclin D1 was reported to be overexpressed in 30–50%
of invasive primary breast cancers and to play a key role in medi-
ating mitogenic response to steroids and growth factor in breast
cancer cells in vitro (Buckley et al, 1993; Dutta et al, 1995;
McIntosh et al, 1995). In addition, it was reported that the
abnormal expression of tumour suppressor genes such as p16 or
pRb was present in 40% of breast cancer (Cairns et al, 1995;
Herman et al, 1995; Pietilainen et al, 1995). Both breast cancer and
endometrial cancer are sex steroid-dependent tumours. Studies in
mice have demonstrated that cyclin D1 plays a pivotal role in
normal mammary gland development. Cyclin D1 knockout mice
fail to undergo the lobular proliferative changes normally seen in
the breast epithelial compartment under the influence of steroid
hormones in pregnancy (Sicinski et al, 1995), whereas overexpres-
sion of cyclin D1 in the mammary gland of transgenic animals
results in premature lobulo-alveolar development, abnormal
epithelial proliferation in pregnancy, and the late development of
adenocarcinoma (Wang et al, 1994). It was demonstrated that
cyclin D1 and oestrogen receptor (ER) gene expression are posi-
tively correlated in primary breast cancer (Zuberberg et al, 1995;
Hui et al, 1996) and that oestrogen stimulation increases cyclin D1
gene expression in an ER-positive cultured breast cancer cell line
(Prall et al, 1997). The mechanism of development and carcino-
genesis of endometrium may differ from that of mammary gland
tissue.
In this study, expression of CDK4 significantly increased from
PE to EC. However, it did not significantly increase with the
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Table 3 Correlation of expression of p16, CDK4, CDK6, CCND1, CCND2, CCND3 and pRb and clinicopathologic features
Clinicopathologic CDK4 CDK6 CCND1 CCND2 CCND3
features NO p16 pRb 1+ or 2+ 2+ 1+ or 2+ 1+ 1+ 1+ Pathway
Proliferative 10 2 (20.0%) 10 (100%) 2 (20.0%)** 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) –
Hyperplasia 18 9 (50.0%)* 18 (100%) 14 (77.8%)** 1 (5.6%)*** 2 (11.1%) 0 (0%)**** 0 (0%) 0 (0%) –
Cancer 35 29 (82.9%)* 31 (88.6%) 27 (77.1%) 12 (34.3%)*** 4 (11.4%) 10 (28.6%)**** 1 (2.9%) 0 (0%) 18 (51.4%)
Clinical stage
I 23 20 (87.0%) 20 (87.0%) 16 (69.6%) 6 (26.1%) 2 (8.7%) 5 (21.7%) 0 (0%) 0 (0%) 10 (43.5%)
II III RE 12 9 (75.0%) 11 (91.7%) 11 (91.7%) 6 (50.0%) 2 (16.7%) 5 (41.7%) 1 (8.3%) 0 (0%) 8 (66.7%)
Histologic grade 
G1 17 15 (88.2%) 15 (88.2%) 13 (76.4%) 5 (29.4%) 1 (5.9%) 3 (17.6%) 1 (5.9%) 0 (0%) 8 (47.1%)
G2 13 11 (84.6%) 12 (92.3%) 9 (69.2%) 4 (30.8%) 2 (15.4%) 5 (38.5%) 0 (0%) 0 (0%) 6 (46.2%)
G3 5 3 (60.0%) 4 (80.0%) 5 (100%) 3 (60.0%) 1 (20.0%) 2 (40.0%) 0 (0%) 0 (0%) 4 (80.0%)
Pathway: p16-cyclin D/CDK-pRb pathway. *P = 0.0119, **P = 0.0054, ***P = 0.039, ****P = 0.0118.progression from stage 1 to 3. These data suggest that the overex-
pression of CDK4 protein is important in the early stages of
endometrial oncogenesis.
The meaning of loss of p16 expression in EH remains unclear.
The loss of p16 protein in EH may be precursors to tumorigenesis.
Four of nine p16 (–) EH (44.4%) had methylation in 5¢CpG island
in the promoter region of the p16 gene. The methylation of the
5¢CpG island of p16/CDKN2 is thought to be associated with inac-
tivation of this tumour suppressor gene. However, the fact that the
loss of p16 protein was significantly higher in EH than EC is
contradictory. It is possible that in EH, the loss of p16 protein with
methylation may differ from that without methylation. Another
speculation is that the loss of p16 protein may be involved in
normal cell function. The loss of p16 protein was significantly
higher in EH than in EC and one of the six p16 (–) EC was consid-
ered to have reduced gene dosage consistent with possible
homozygous deletion of the CDKN2 gene, whereas none of the
nine p16 (–) EH showed such reduced gene dosage. The fact that
five of 15 EH (33.3%) had methylation in 5¢CpG island in the
promoter region of the p16 gene may be contradictory; however,
Gonzalez reported that p16/CDKN2 was methylated and not
expressed in the 50% of normal colon tissue (Gonzalez et al,
1995). It has been reported that overexpression of p16 might be an
important early event in neoplastic transformation (Bartkova et al,
1996; Shiozawa et al, 1997; Shigemasa et al, 1997). Yao et al
(1998) reported that primary soft tissue sarcoma overexpressing
CDK4 also had high levels of pRb and/or p16, which may reflect
the onset of feedback to counteract the overexpression of CDK4. It
may be that the loss of p16 in EH is a reversible change of the
feedback system between CDK4 and p16. Further examination
will be required to determine if the transcriptional silencing of
p16/CDKN2 observed in EH is involved in normal cell function or
is a precursor to tumorigenesis.
In conclusion, the expression of p16 and CDK4 may be an early
event in the neoplastic transformation of endometrial cancer.
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